KERYX BIOPHARMACEUTICALS INC KERX Income Statement

Keryx biopharmaceuticals inc (KERX)

Income statement / TTM

Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Net U.S. Auryxia product sales
License
Cost of goods sold
Revenues:
Revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net U.S. Auryxia product sales
-	75,620	65,631	55,514	-	37,899	32,062	27,173	23,715	21,856	15,335	10,141	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License revenue
-	5,558	4,942	5,127	-	4,934	4,915	4,810	4,518	4,248	3,995	3,539	3,095	2,334	1,578	10,825	10,256	10,000	10,000	7,000	0	0	0	-	-	-	-	5,000	0	0	0	-	-
Total revenues
-	81,178	70,573	60,641	-	42,833	36,977	31,983	28,233	26,104	19,330	13,680	8,466	4,514	2,000	10,825	0	0	0	-	-	-	-	-	-	-	-	5,000	0	0	0	-	-
Costs and expenses:
Cost of goods sold
-	30,332	27,283	21,955	-	40,285	41,005	37,803	25,441	10,310	5,515	4,520	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License expense
-	3,334	2,964	3,076	-	2,961	2,949	2,886	2,711	2,550	2,398	2,124	1,857	1,400	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	699	690	822	803	938	1,220	0	0	0
Other research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	21,292	26,144	28,713	26,209	23,434	17,943	0	0	0
Research and development
37,686	39,065	39,303	37,679	31,236	30,635	28,652	29,504	31,309	33,785	34,719	36,694	34,519	42,422	44,734	51,502	56,144	47,761	44,663	34,734	29,180	22,439	19,061	20,031	21,991	26,834	29,535	27,012	24,372	19,163	0	0	0
Selling, general and administrative
109,788	106,081	102,356	99,622	93,870	91,645	86,847	84,553	83,081	82,765	83,339	81,410	93,897	90,139	81,645	70,057	41,069	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	1,458	1,394	1,343	1,289	1,239	1,180	0	0	0
Other general and administrative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	5,653	5,703	5,572	5,448	5,370	5,463	0	0	0
General and administrative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	0	-	7,111	7,097	6,915	6,737	6,609	6,643	0	0	0
Total costs and expenses
182,819	178,812	171,906	162,332	156,078	165,526	159,453	154,746	142,542	129,410	125,971	124,748	133,718	134,341	127,402	122,054	99,587	79,665	68,576	54,083	43,022	32,816	27,061	27,079	29,102	33,931	36,450	33,749	30,981	25,806	0	0	0
Operating loss
-88,601	-97,634	-101,333	-101,691	-104,586	-122,693	-122,476	-122,763	-114,309	-103,306	-106,641	-111,068	-125,252	-129,827	-125,402	-111,229	-89,331	-69,665	-58,576	-47,083	-36,022	-25,816	-20,061	-27,079	-29,102	-33,931	-31,450	-28,749	-25,981	-20,806	0	0	0
Other income (expense):
Amortization of debt discount
0	0	-	62,965	0	0	-	34,227	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income (expense), net
364	700	1,089	981	836	745	-2,112	-4,025	-16,476	-16,526	-13,893	-11,987	373	382	397	411	430	402	369	351	330	300	1,760	1,719	1,749	1,806	372	380	385	303	0	0	0
Total other income (expense)
0	0	-	-61,984	0	0	-	-38,252	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss before income taxes
-91,767	-98,250	-163,209	-163,675	-166,715	-184,913	-143,067	-161,015	-165,012	-154,059	-136,282	-123,055	-124,879	-129,445	-125,005	-110,818	-88,901	-69,263	-58,207	-46,732	-35,692	-25,516	-18,301	-25,360	-27,353	-32,125	-31,078	-28,369	-25,596	-20,503	0	0	0
Income tax expense (benefit)
-929	-909	-889	-235	80	80	80	80	83	85	88	90	767	0	0	0	-	0	-	0	0	0	0	-	0	0	0	0	0	0	0	0	0
Loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-28,369	0	0	0	-	-
Gain from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	246	0	0	0	-	-
Loss before extraordinary gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-
Extraordinary gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-
Net loss
-90,838	-97,341	-162,320	-163,440	-166,795	-184,993	-143,147	-161,095	-165,095	-154,144	-136,370	-123,145	-125,646	-130,190	-125,727	-111,518	-88,901	-69,263	-58,207	-46,732	-35,692	-25,516	-15,662	-22,721	-24,468	-29,240	-30,832	-28,123	-25,596	-20,503	0	0	0
Loss before extraordinary gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.08	-	-	-	-	-	-	-	-
Continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.12	-0.15	-0.05	-0.10	-	-
Discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	-	-
Extraordinary gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.04	-	-	-	-	-	-	-
Basic and diluted net loss per common share (in dollars per share)
-0.14	-0.18	-0.18	-0.26	-0.20	-0.77	-0.21	-0.32	-0.39	-0.42	-0.39	-0.36	-0.29	-0.26	-0.28	-0.44	-0.38	-0.24	-0.15	-0.22	-0.19	-0.14	-0.03	-0.09	-0.08	-0.02	-0.13	-0.12	-0.15	-0.05	-0.10	-0.10	-0.09
Weighted average shares used in computing basic and diluted net loss per common share (in shares)
120,432	120,451	119,844	119,376	118,992	112,590	107,071	-	-	-	-	-	-	-	-	92,122	91,846	91,516	88,517	82,485	81,823	81,739	77,990	71,931	71,910	71,466	71,225	-	-	-	-	-	-
Weighted average shares used in computing basic and diluted net loss per common share
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	59,324	58,426